Drugs / 68Ga-NOTA-RM26
68Ga-NOTA-RM26
also known as
[68Ga]Ga-NOTA-RM26
Diagnostic / imaging agent targets GRPR via inhibition
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05001204 | May 2021 → Aug 2022 | gastrointestinal stromal tumor | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT03347864 | Oct 2016 → Oct 2018 | breast neoplasm | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03164837 | Nov 2016 → Nov 2018 | prostate cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NOTA-RM26 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03164837 ↗ |
| Known as | [68Ga]Ga-NOTA-RM26 | “This study was designed to evaluate a gastrin-releasing peptide receptor antagonist PET tracer, [68Ga]Ga-NOTA-RM26, and compare it with [18F]FDG PET/CT in the assessment of...” PMID 39448271 ↗ Feb 2025 |
| Action | Inhibit | “RM26, a GRPR antagonist with high affinity, was discovered by peptide backbone modification of bombesin analogues.” NCT03347864 ↗ |
| Modality | Diagnostic / imaging agent | “positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-RM26” NCT03164837 ↗ |
| Route | Intravenous | “111-148 MBq of 68Ga-NOTA-RM26 in one dose intravenously” NCT03164837 ↗ |
| Target | GRPR | “To target gastrin-releasing peptide receptor in neoplastic cells of human prostate cancer” NCT03164837 ↗ |